Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (BHC) delivers innovative healthcare solutions across gastroenterology, dermatology, and eye health through brands like Bausch + Lomb and Salix Pharmaceuticals. This page provides investors and industry professionals with a comprehensive repository of official company announcements and market-relevant updates.
Key resources include: earnings reports, regulatory filings, product launch announcements, and partnership developments. All content is sourced directly from BHC’s verified communications to ensure accuracy and timeliness.
Regularly updated with press releases spanning therapeutic advancements, financial results, and operational milestones. Bookmark this page to monitor BHC’s strategic initiatives within the global pharmaceutical landscape.
Bausch Health Companies Inc. (BHC) announced a planned separation of its eye health business, Bausch + Lomb, which intends to enter a new credit agreement. This agreement includes a $2.5 billion term loan and a $500 million revolving credit facility, both maturing in 2027. The funds from the term loan will be used to repay an intercompany note to Bausch Health following Bausch + Lomb's initial public offering. The completion of these transactions is subject to market conditions and other approvals, anticipated to close in Q2 2022.
Bausch Health (NYSE/TSX: BHC) announced the presentation of 10 podium and 2 poster presentations at the upcoming American Society of Cataract and Refractive Surgery annual meeting, from April 22-26, 2022, in Washington, D.C. Key highlights include results from the pivotal Phase 3 trial of NOV03, aimed at treating dry eye disease associated with Meibomian gland dysfunction. The trial results will be featured in a presentation titled "Efficacy of Perfluorohexyloctane on Signs and Symptoms of Dry Eye Disease: The Gobi Study." Bausch + Lomb aims to support surgeons with ongoing scientific exchange.
Salix Pharmaceuticals, part of Bausch Health Companies (BHC), announced it will present four research posters at the Society of Hospital Medicine (SHM) Converge 2022, held from April 7-10 in Nashville, TN. The featured studies cover XIFAXAN® (rifaximin) for hepatic encephalopathy and RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation. Key findings include XIFAXAN’s effectiveness in reducing emergency department visits and RELISTOR’s safety profiles. These presentations aim to enhance awareness of treatment options in gastroenterology.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to reduce debt by $200 million by paying down senior secured term loans on March 31, 2022. This strategic move will be financed through cash generated from operations, demonstrating the company's commitment to improving its financial health. Bausch Health continues to focus on enhancing its portfolio in therapeutic areas such as eye health, gastroenterology, and dermatology.
Bausch Health and Clearside Biomedical announced the U.S. commercial launch of XIPERE®, the first FDA-approved therapy for suprachoroidal injection, designed to treat macular edema associated with uveitis. This therapy aims to address a serious condition affecting approximately 300,000 Americans, which can lead to vision loss. Key features include targeted delivery through the proprietary SCS Microinjector®, providing higher bioavailability and lower side effects compared to traditional methods. Training for eye care professionals on administration techniques is highlighted as crucial for successful implementation.
Bausch Health Companies (NYSE/TSX: BHC) announced a study demonstrating that FDA-approved medications for opioid-induced constipation (OIC), particularly RELISTOR®, significantly reduce hospitalization rates and costs. Research published in Advances in Therapy showed a 64% lower chance of hospitalization for OIC patients treated with OIC-Rx compared to those who were not. Furthermore, patients treated with RELISTOR had a reduction of $781 in healthcare costs per emergency department encounter. The study highlights the potential healthcare benefits and cost-effectiveness of using RELISTOR in OIC management.
Solta Medical Corporation, a subsidiary of Bausch Health Companies Inc. (BHC), has appointed Gary Gemignani as Chief Financial Officer, effective March 28, 2022. Gemignani brings over 35 years of experience in finance, previously serving as CFO for various pharmaceutical firms. His extensive background is expected to support Solta as it prepares for a potential IPO following a public filing on February 8, 2022. The IPO will involve Solta’s common shares, pending market conditions and regulatory approvals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced new analyses for its dermatology products IDP-126 Gel, DUOBRII®, and SILIQ® at the AAD Annual Meeting from March 25-29, 2022. The investigational IDP-126 Gel aims to treat moderate-to-severe acne and could become a first-in-class therapy if approved. DUOBRII® effectiveness for maintaining skin clearance was also highlighted. Additionally, the company introduced a JUBLIA® virtual reality experience to educate about onychomycosis, impacting 35 million people in the U.S. annually.
Bausch Health Companies (NYSE/TSX: BHC) announced participation in two upcoming investor conferences. The events include the Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 11:15 a.m. ET. Key executives participating include Joseph C. Papa, Sam Eldessouky, and Arthur J. Shannon. Live webcasts will be available on the company's Investor Relations page.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
